ketamine has been researched along with Migraine Disorders in 12 studies
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.
Migraine Disorders: A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Although low-dose ketamine demonstrates analgesic efficacy for acute pain complaints in the ED, headaches have historically been excluded from these trials." | 5.27 | Low-dose Ketamine Does Not Improve Migraine in the Emergency Department: A Randomized Placebo-controlled Trial. ( Bos, L; Etchison, AR; Heitz, C; McAllister, KB; Mohammed, M; Park, B; Phan, AV; Ray, M, 2018) |
| "The available evidence from preclinical studies is helping to translate the role of ketamine in blocking spreading depolarizations to clinical practice, in the settings of migraine with aura, traumatic brain injury, subarachnoid hemorrhage, and hemorrhagic and ischemic stroke." | 5.12 | Cortical spreading depolarization and ketamine: a short systematic review. ( Coelho, ACSDS; Figueiredo, EG; Rabelo, NN; Teixeira, MJ; Telles, JPM; Welling, LC, 2021) |
| "Subanesthetic ketamine infusion has been used for managing refractory headache in inpatient or outpatient infusion settings." | 4.31 | Real-world study of intranasal ketamine for use in patients with refractory chronic migraine: a retrospective analysis. ( Lauritsen, CG; Marmura, MJ; Natekar, A; Park, J; Viscusi, ER; Yuan, H, 2023) |
| "Migraine is a debilitating disorder affecting females more frequently than males." | 3.01 | The NMDA receptor antagonists memantine and ketamine as anti-migraine agents. ( Borończyk, A; Borończyk, M; Czarnacki, K; Paprocka, J; Podkowa, K, 2023) |
| "Many patients with refractory chronic migraine have experienced treatment failure with the Raskin protocol." | 2.72 | Beyond the Raskin Protocol: Ketamine, Lidocaine, and Other Therapies for Refractory Chronic Migraine. ( Lauritsen, C; Mojica, JJ; Nahas, SJ; Schwenk, ES, 2021) |
| "Patients with refractory chronic migraine have substantial disability and have failed many acute and preventive medications." | 1.62 | Ketamine for Refractory Chronic Migraine: An Observational Pilot Study and Metabolite Analysis. ( Denk, W; Katz, D; Lauritsen, C; Lovett, J; Moaddel, R; Schwenk, ES; Silberstein, SD; Torjman, MC; Wainer, IW, 2021) |
| "Ketamine has recently emerged as a promising therapeutic alternative for abortive migraine therapy, likely secondary to N-methyl-d-aspartate antagonism." | 1.56 | Intranasal Ketamine for Abortive Migraine Therapy in Pediatric Patients: A Single-Center Review. ( Miller, E; Perry, MS; Ryals, B; Shandley, S; Turner, AL, 2020) |
| "Ketamine was administered using a standard protocol starting with a dose of 0." | 1.43 | Intravenous ketamine for subacute treatment of refractory chronic migraine: a case series. ( Ashina, S; Lauritsen, C; Lipton, RB; Mazuera, S, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 6 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mojica, JJ | 1 |
| Schwenk, ES | 2 |
| Lauritsen, C | 3 |
| Nahas, SJ | 1 |
| Podkowa, K | 1 |
| Czarnacki, K | 1 |
| Borończyk, A | 1 |
| Borończyk, M | 1 |
| Paprocka, J | 1 |
| Yuan, H | 1 |
| Natekar, A | 1 |
| Park, J | 1 |
| Lauritsen, CG | 1 |
| Viscusi, ER | 1 |
| Marmura, MJ | 1 |
| Turner, AL | 1 |
| Shandley, S | 1 |
| Miller, E | 1 |
| Perry, MS | 1 |
| Ryals, B | 1 |
| Telles, JPM | 1 |
| Welling, LC | 1 |
| Coelho, ACSDS | 1 |
| Rabelo, NN | 1 |
| Teixeira, MJ | 1 |
| Figueiredo, EG | 1 |
| Torjman, MC | 1 |
| Moaddel, R | 1 |
| Lovett, J | 1 |
| Katz, D | 1 |
| Denk, W | 1 |
| Silberstein, SD | 1 |
| Wainer, IW | 1 |
| Etchison, AR | 1 |
| Bos, L | 1 |
| Ray, M | 1 |
| McAllister, KB | 1 |
| Mohammed, M | 1 |
| Park, B | 1 |
| Phan, AV | 1 |
| Heitz, C | 1 |
| Bogdanov, VB | 1 |
| Middleton, NA | 1 |
| Theriot, JJ | 1 |
| Parker, PD | 1 |
| Abdullah, OM | 1 |
| Ju, YS | 1 |
| Hartings, JA | 1 |
| Brennan, KC | 1 |
| Mazuera, S | 1 |
| Lipton, RB | 1 |
| Ashina, S | 1 |
| Nicolodi, M | 3 |
| Sicuteri, F | 3 |
| Del Bianco, PL | 1 |
3 reviews available for ketamine and Migraine Disorders
| Article | Year |
|---|---|
Beyond the Raskin Protocol: Ketamine, Lidocaine, and Other Therapies for Refractory Chronic Migraine.
Topics: Analgesics; Humans; Ketamine; Lidocaine; Migraine Disorders; Prospective Studies | 2021 |
The NMDA receptor antagonists memantine and ketamine as anti-migraine agents.
Topics: Animals; Excitatory Amino Acid Antagonists; Female; Ketamine; Male; Memantine; Migraine Disorders; R | 2023 |
Cortical spreading depolarization and ketamine: a short systematic review.
Topics: Animals; Cortical Spreading Depression; Humans; Ketamine; Migraine Disorders; Prospective Studies; R | 2021 |
2 trials available for ketamine and Migraine Disorders
| Article | Year |
|---|---|
Low-dose Ketamine Does Not Improve Migraine in the Emergency Department: A Randomized Placebo-controlled Trial.
Topics: Acute Pain; Adult; Anesthetics, Dissociative; Double-Blind Method; Emergency Service, Hospital; Fati | 2018 |
Exploration of NMDA receptors in migraine: therapeutic and theoretic implications.
Topics: Adult; Asthenia; Cross-Over Studies; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; | 1995 |
7 other studies available for ketamine and Migraine Disorders
| Article | Year |
|---|---|
Real-world study of intranasal ketamine for use in patients with refractory chronic migraine: a retrospective analysis.
Topics: Adult; Analgesics; Female; Headache; Humans; Ketamine; Male; Migraine Disorders; Prospective Studies | 2023 |
Intranasal Ketamine for Abortive Migraine Therapy in Pediatric Patients: A Single-Center Review.
Topics: Administration, Intranasal; Adolescent; Child; Excitatory Amino Acid Antagonists; Female; Humans; Ke | 2020 |
Ketamine for Refractory Chronic Migraine: An Observational Pilot Study and Metabolite Analysis.
Topics: Adult; Analgesics; Chronic Disease; Female; Humans; Ketamine; Lidocaine; Male; Middle Aged; Migraine | 2021 |
Susceptibility of Primary Sensory Cortex to Spreading Depolarizations.
Topics: Animals; Brain Injuries; Cortical Spreading Depression; Humans; Ketamine; Male; Mice; Mice, Inbred C | 2016 |
Intravenous ketamine for subacute treatment of refractory chronic migraine: a case series.
Topics: Adult; Chronic Disease; Excitatory Amino Acid Antagonists; Female; Humans; Infusions, Intravenous; K | 2016 |
Modulation of excitatory amino acids pathway: a possible therapeutic approach to chronic daily headache associated with analgesic drugs abuse.
Topics: Acetates; Adult; Amines; Chronic Disease; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagon | 1997 |
Negative modultors of excitatory amino acids in episodic and chronic migraine: preventing and reverting chronic migraine. Special lecture 7th INWIN Congress.
Topics: Acetates; Adult; Amines; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Enzyme Inhibitors; E | 1998 |